Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


ADOPT was a pragmatic, real-life, double-blind, randomised multicentre study which was evaluating specifically whether thiazolidinediones, with their different mode of action, can provide more durable glycaemic control than metformin or sulphonylureas. By utilising a monotherapy approach, in people with T2DM diagnosed for less than three years who are antihyperglycaemic agent naïve, ADOPT was designed to compare the relative efficacy of these three oral agents as judged primarily by the time to monotherapy failure. ADOPT will provide data on the effect of mechanistically differing treatment options on metabolic control, beta cell function, and markers of macrovascular disease risk in type 2 diabetes.


The ADOPT results were announced at the IDF 19th World Diabetes Congress in Cape Town on Monday 4th December at 16.30 local time and simultaneously published in the New England Journal of Medicine.

Sponsor GlaxoSmithKline
Reference number NCT00279045

ADOPT Conference Abstracts